Myostatin inhibitors explained: the pathway, the antibodies and why muscle matters in GLP-1 weight loss

A myostatin inhibitor is any molecule that blocks the signal that tells skeletal muscle to stop growing. Myostatin, also called growth differentiation factor 8 (GDF8), and its relative activin A act through the activin type II receptors to hold muscle mass in check, and the drugs that interrupt that pathway are now the most closely watched companions to GLP-1 weight-loss medicines. This article explains the pathway, the four monoclonal antibodies that have reported clinical results, the earlier approaches that did not make it, why muscle preservation has become the central question in obesity treatment, whether they build muscle, when they could be available, and why none of these molecules can be bought. It exists because people reading our retatrutide page ask about them. It describes the research; it is not guidance on using anything.

Why does muscle loss on weight-loss jabs matter?

In shortWeight-loss jabs don't only remove fat: on semaglutide alone, about 1 kg in every 3 lost was muscle. That is the problem these drugs aim to fix.

The GLP-1 receptor agonists, and the multi-agonists such as retatrutide that follow them, produce weight loss of a size that used to need surgery. The cost is that not all of the weight is fat. In the semaglutide arm of COURAGE, 33% of the weight lost was lean mass; in the tirzepatide arm of EMBRAZE it was 30%. Lean mass includes water, organ and bone as well as muscle, and some loss is expected when a smaller body needs less muscle to move, but the concern is threefold: strength and function in older people, the drop in resting metabolic rate that makes regain easier, and the finding that weight regained after stopping tends to return as fat. Regeneron's own framing, in its September 2025 release, is that patients who cycle off treatment "can regain almost all of the weight lost, but mostly in the form of fat". The antibodies are being tested to change the composition of the loss, not its size.

The maths: what does adding an antibody change?

In shortSame weight lost, far more of it fat and far less of it muscle.

Every number below comes from a published trial. The sums are simple: weight lost is made of fat lost plus lean mass lost, and the antibodies change the split, not the size.

Two caveats keep the maths honest. The trials used different GLP-1 drugs, people and durations, so the arms are not a head-to-head league table. And the strongest combination, the COURAGE triplet, came with a 30.9% discontinuation rate for side effects and two deaths, against 4.6% on semaglutide alone; a better split is not the same as a better drug. None of this is guidance on using anything; these are trial results for medicines that are not available outside clinical studies.

What are the four drugs, and what did each show?

In shortFour drugs from four companies, each blocking the muscle brake at a different point.

When will these drugs be available?

In shortTwo are approved in the US for rare diseases. None is approved for weight loss, and we don't expect one before about 2030.

Short answer: two are approved, but only in the United States and only for rare diseases. For weight loss, none is approved anywhere, none has started a phase 3 obesity trial, and none is licensed in the UK. Status below is as of 1 October 2026.

The originator antibodies are not sold: these are full-size biologics made in cell culture. ALTA supplies research-grade versions of all four, made by a third-party manufacturer, as laboratory reagents only. The status table further down this article has every approval, price and filing in one place.

Can myostatin inhibitors build muscle? The honest answer

In shortIn trials they kept muscle during weight loss and added a little in some people, but nothing like the bodybuilding claims.

The trial record says that blocking myostatin or activin signalling adds a few percent of lean tissue on a scan, in the right population, over a year or more, and has not made healthy adults stronger because it has never been tested in them. The drugs that do it are antibodies given under medical supervision in trials or for rare diseases, and none of the originator antibodies can be bought. Research-grade versions are laboratory reagents with no human data outside the trials, and other products sold under myostatin names, such as YK-11, are something else. For what the antibodies are being developed to do, which is to keep muscle during GLP-1 weight loss, see muscle loss on GLP-1 peptides; for their status and prices, the availability section and bimagrumab price and availability; for their side effects, trevogrumab side effects and bimagrumab side effects. ALTA PEPTIDES supplies research-grade versions of the four antibodies as laboratory reagents under our research use policy, and stocks no YK-11, no follistatin and no ACE-031.

Are myostatin inhibitors banned in sport?

In shortYes. WADA bans the whole class at all times.

The myostatin inhibitor WADA position is unambiguous. The 2026 WADA Prohibited List places the whole class in section S4.3, "Agents preventing activin receptor IIB activation", which names activin A-neutralising antibodies, activin receptor IIB competitors such as ACE-031, anti-activin receptor IIB antibodies such as bimagrumab, and myostatin inhibitors including agents that reduce or ablate myostatin expression, myostatin-binding proteins and myostatin-neutralising antibodies. Substances in S4.3 are classed as non-specified, which affects how a finding is sanctioned, and they are prohibited at all times, in and out of competition. Garetosmab, trevogrumab and apitegromab all fall within that wording. Anyone in tested sport should treat every product in this article as banned, including the ones that do not contain what the label says, because WADA tests for the substance, not the label.

What is sold online as a myostatin inhibitor?

In shortNot the real antibodies. Those can't be made like peptides, so the vials contain something else.

The clinical myostatin inhibitors are monoclonal antibodies: proteins of about 150 kilodaltons made in mammalian cell culture, never supplied outside their sponsors' trials and hospital programmes, and impossible to make by peptide synthesis. A myostatin peptide, as sold, is therefore never one of them. Three things appear under the label. YK-11 is a synthetic steroidal compound described in cell studies as SARM-like and as raising follistatin expression in cultured muscle cells; it is not a myostatin antibody, has never been in a clinical trial, and belongs in the anabolic-steroid conversation. Vials labelled follistatin 344 claim to contain the 344-amino-acid follistatin protein, a folded glycoprotein that is not a candidate for research-peptide synthesis and whose contents cannot be verified from a vendor certificate. Vials labelled ACE-031 claim to contain a discontinued fusion protein that Acceleron never released. Bimagrumab bodybuilding listings and myostatin inhibitor bodybuilding forums trade in all three. The honest description of all of them is unknown substance, unverified label.

Do they replace retatrutide and GLP-1 drugs?

In shortThey don't replace weight-loss jabs. They are tested alongside them, to protect muscle.

They are not competitors to retatrutide; they are being designed as companions. Every antibody trial above pairs the antibody with a GLP-1 drug, because the antibodies alone produce little weight loss (bimagrumab alone lost 10.8% at 72 weeks, less than semaglutide) and the GLP-1 drugs alone lose muscle. The combinations are still phase 2, the earliest phase 3 readouts for obesity are years away, and the two approvals so far are for rare diseases. Retatrutide, by contrast, has completed phase 3 trials for obesity; our phase 3 summary and GLP-1 explainer cover it, and the weight and metabolic category lists what we supply.

How does the muscle brake work?

In shortYour body has a built-in brake on muscle growth called myostatin. These drugs take the foot off it.

Myostatin was identified in 1997 when mice lacking the gene were found to have individual muscles weighing two to three times more than normal. Cattle breeds with natural myostatin mutations (Belgian Blue, Piedmontese) show the same double-muscled build, and a handful of humans with loss-of-function mutations have been described. The protein is made in muscle as an inactive precursor, promyostatin, which is cut to a latent form and then to mature myostatin. Mature myostatin and activin A both bind the activin type II receptors, ActRIIA and ActRIIB, on the muscle cell surface. That binding recruits a type I receptor and switches on SMAD2/3 signalling inside the cell, which suppresses protein synthesis and muscle growth.

Each step is a place to intervene, and the four antibodies below differ mainly in where they act. Apitegromab binds promyostatin and latent myostatin, before activation. Trevogrumab binds mature myostatin. Garetosmab binds activin A. Bimagrumab binds the receptors themselves, blocking myostatin, activin and other ligands together. The further down the chain you block, the broader the effect, and the broader the effect the more off-target biology you touch.

What was tried before, and why did it fail?

In shortEarlier attempts failed on side effects or weak results.

Myostatin inhibition has a long record of trials that grew muscle on a scan but did not improve function. Wyeth's stamulumab (MYO-029), the first anti-myostatin antibody in people, was tested in 116 adults with muscular dystrophies and showed no significant difference in muscle mass or function. Pfizer's domagrozumab and Lilly's landogrozumab followed the same path and were discontinued for lack of efficacy.

ACE-031 (Acceleron and Shire) was different in design: a soluble ActRIIB receptor fused to an antibody fragment, a "ligand trap" that soaked up myostatin and activins before they reached the cell. In a Duchenne muscular dystrophy trial it produced early gains in lean mass, but development was halted in 2011 after nosebleeds, gum bleeding and telangiectasias (visible dilated small vessels), attributed to the trap also binding BMP9 and BMP10, proteins involved in blood vessel maintenance. That episode is why the field moved to more selective molecules, and why bimagrumab's receptor-level approach is watched closely for the same signals.

Follistatin is the body's own binder of myostatin and activins. Acceleron's follistatin-based ACE-083 was injected into specific muscles in facioscapulohumeral dystrophy; it increased muscle volume on MRI but did not improve function and was discontinued. ACE-2494, a systemic follistatin-based agent, was discontinued in phase 1 because healthy volunteers developed anti-drug antibodies. The "follistatin 344" and "follistatin peptide" products sold online are not these molecules and have no trial data of any kind.

YK-11 is worth naming only to rule it out. It is a synthetic steroidal compound, described in cell studies as SARM-like and as raising follistatin expression in cultured muscle cells. It is not a myostatin antibody, it has never been in a clinical trial, and it belongs in the anabolic-steroid conversation rather than this one.

What do the trials show in older adults and muscle disease?

In shortIn older adults and muscle-wasting diseases, muscle grew on scans but strength and function mostly didn't improve.

Before obesity, the class was tested where muscle growth would matter most, and the pattern was set early. Wyeth's MYO-029 (stamulumab), the first anti-myostatin antibody in people, was given to 116 adults with muscular dystrophies in a phase 1/2 trial published in Annals of Neurology in 2008; it showed no significant difference in muscle mass or function. Pfizer's domagrozumab and Lilly's landogrozumab were discontinued for lack of efficacy. In sarcopenia, Regeneron's trevogrumab produced small lean mass gains at all three doses in around 250 adults aged 70 and over without a significant improvement in strength or walking tests, and Novartis's bimagrumab, in a trial published in JAMA Network Open in 2020, grew muscle without a clear functional advantage over optimised standard care. In inclusion body myositis, bimagrumab's RESILIENT trial of 251 participants missed its six-minute walk endpoint. The partial exception is apitegromab, which improved motor function in children with spinal muscular atrophy in the SAPPHIRE trial and was approved for that disease in September 2026; our apitegromab article covers it. Even there, the gain was measured against decline on placebo, in a neuromuscular disease, on top of SMN-targeted treatment, and the label carries a fracture warning.

The trevogrumab and garetosmab pair belongs in this section only to be ruled out. Searches for trevogrumab and garetosmab for muscle growth have grown since the COURAGE results, but COURAGE measured lean mass preserved during weight loss on semaglutide, not muscle gained; the triplet arm lost 2.0% of lean mass rather than adding any, with a 30.9% discontinuation rate and two deaths. Our trevogrumab and garetosmab results has the figures. Nothing in the record supports either antibody as a muscle-building agent.

Status of all four antibodies (updated 29 September 2026)

In shortEvery antibody's approvals, prices and next step, in one table.

Is any myostatin inhibitor approved for weight loss?

In shortNo. None is approved anywhere for weight loss or for protecting muscle during it.

No myostatin inhibitor is approved anywhere for weight loss or for preserving muscle during weight loss, and none produces large weight loss alone: bimagrumab, the strongest, lost 10.8% at 72 weeks against 15.7% for semaglutide. All four have been tested as add-ons to semaglutide or tirzepatide in phase 2, all four preserved lean mass to some degree, and none has entered phase 3 for that use. A myostatin inhibitor price for weight loss therefore does not exist. The UK path for any of them would be an MHRA licence followed by a NICE appraisal, neither of which has begun. Muscle loss on GLP-1 peptides gives the figures the antibodies are trying to change, and the muscle growth section deals with the bodybuilding claims and the WADA ban.

Can you buy them? What ALTA PEPTIDES supplies

In shortThese are antibodies, not peptides. Nobody can sell them as research chemicals, us included.

Trevogrumab, garetosmab, apitegromab and bimagrumab are monoclonal antibodies: full-size immunoglobulins made in mammalian cell culture, given by intravenous infusion or subcutaneous injection in a clinical setting. They are not peptides and they cannot be synthesised the way a peptide is; research-grade versions are recombinant antibodies made in cell culture by specialist manufacturers. The originator products are not sold outside trials or prescription supply, so a research-grade vial is never the branded medicine; its identity rests on the manufacturer's certificate of analysis. ALTA PEPTIDES supplies research-grade versions of these antibodies as laboratory reagents under our research use policy: recombinant antibodies made by a third-party manufacturer, not the products of the originator companies. These articles are here so that people who search for these names find an accurate account rather than a counterfeit.

Sources

• Regeneron press release, 17 September 2025: complete 26-week results from the phase 2 COURAGE trial (trevogrumab, garetosmab and semaglutide), presented at EASD.
• Regeneron press release, 17 September 2025: positive phase 3 OPTIMA trial of garetosmab in adults with FOP; FDA approval of PASATRU (garetosmab-grts) announced 19 August 2026.
• Scholar Rock press release, 11 September 2026: FDA approval of ISEMBYLD (apitegromab-mstn) for spinal muscular atrophy.
• Scholar Rock press release, 18 June 2025, and Nature Medicine 2026: phase 2 EMBRAZE trial of apitegromab with tirzepatide.
• Heymsfield et al., Nature Medicine, March 2026: phase 2b BELIEVE trial of bimagrumab and semaglutide; presented at ADA, June 2025.
• Muscular Dystrophy Association, April 2011: ACE-031 Duchenne trials halted; BioCentury: Acceleron discontinues ACE-2494 due to anti-drug antibodies; Acceleron press releases on ACE-083 phase 2 in FSHD.
• Wagner et al., Annals of Neurology 2008: phase 1/2 trial of MYO-029 (stamulumab) in adult muscular dystrophy.
• McPherron, Lawler and Lee, Nature 1997: identification of myostatin (GDF-8) and the double-muscled myostatin-null mouse.
• Regeneron press release, 1 October 2026: "Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss" (52-week lower-dose results, MRI muscle substudy), presented at EASD 2026 and in press with The Lancet.
• ClinicalTrials.gov NCT06643728: phase 2 study of bimagrumab and tirzepatide, alone or in combination, in adults with obesity or overweight (252 enrolled; primary completion January 2026; study completion estimated January 2027).
• Regeneron press release and FDA announcement, 19 August 2026: approval of PASATRU (garetosmab-grts) for adults with FOP; Managed Healthcare Executive and Medical Daily, August 2026: annual list price about $1.4 million, launch range $693,000 to $2.1 million.
• Scholar Rock press release, 11 September 2026: FDA approval of ISEMBYLD (apitegromab-mstn); Reuters and Scrip, 14 September 2026: net annual cost about $310,000, wholesale acquisition cost $11,659 per vial; European Medicines Agency: withdrawal of the Isembyld marketing authorisation application, 13 August 2026.
• Regeneron press release, 17 September 2025: COURAGE 26-week results; EASD 2026 programme and Medscape preview: new COURAGE outcomes to be presented in Milan.
• Heymsfield et al., Nature Medicine, March 2026: BELIEVE trial; Fierce Biotech, 25 September 2025: Lilly withdraws one bimagrumab and tirzepatide phase 2b, continuing phase 2 with results expected in 2026.
• Scholar Rock press release, 18 June 2025, and Nature Medicine 2026: EMBRAZE trial of apitegromab with tirzepatide.
• Heymsfield et al., Nature Medicine, March 2026: BELIEVE phase 2 trial (bimagrumab alone: lean mass +2.5%, fat mass -28.5%, weight -10.8% at 72 weeks).
• Wagner et al., Annals of Neurology, 2008: phase 1/2 trial of MYO-029 in adult muscular dystrophy (116 participants; no significant change in muscle mass or function).
• Rooks et al., JAMA Network Open, 2020: bimagrumab in sarcopenia; Hanna et al., The Lancet Neurology, 2019: RESILIENT trial in inclusion body myositis; ClinicalTrials.gov: phase 2 study of REGN1033 (trevogrumab) in sarcopenia.
• Scholar Rock press release, 11 September 2026: FDA approval of ISEMBYLD (apitegromab) for spinal muscular atrophy; SAPPHIRE results and fracture warning.
• Regeneron press release, 17 September 2025: COURAGE 26-week results (triplet lean mass, discontinuations, deaths).
• Muscular Dystrophy Association, April 2011: ACE-031 trials halted; Acceleron press releases on ACE-083 in FSHD; BioCentury: ACE-2494 discontinued after anti-drug antibodies.
• World Anti-Doping Agency, 2026 Prohibited List, section S4.3 "Agents preventing activin receptor IIB activation".

Questions people ask